Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical co ...

Group 1: Fellowship Announcement - The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology announced the recipients of the first annual CG-SUO-CTC NMIBC Research Fellowship aimed at supporting clinical cancer research in Non-Muscle Invasive Bladder Cancer (NMIBC) [1] - The fellowship recipients, Drs. Saum Ghodoussipour and Taylor Goodstein, were recognized for their innovative research plans that have the potential to advance urology research [1] Group 2: Bladder Cancer Statistics - In 2025, it is estimated that over 84,000 individuals will be diagnosed with bladder cancer, with NMIBC accounting for approximately 75% of these cases [2] - Bladder cancer ranks as the sixth most common cancer in the United States, with men representing three-quarters of newly diagnosed cases [2] Group 3: About SUO-CTC - SUO-CTC is a clinical research network comprising over 600 members from more than 300 clinical sites across the U.S. and Canada, dedicated to advancing urology research [3] - The organization operates as a registered 501c3 not-for-profit corporation and collaborates with the Society of Urologic Oncology (SUO) [3] Group 4: About CG Oncology - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapies for bladder cancer patients [4] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [4] Group 5: Research Focus of Fellowship Recipients - Dr. Saum Ghodoussipour's research focuses on dynamic intra-tumor heterogeneity in NMIBC [5] - Dr. Taylor Goodstein's research involves spatial transcriptomic profiling of the tumor microenvironment in BCG-unresponsive NMIBC patients treated with novel intravesical gene therapies [5]